Company / SG&A Expense
Avidity Biosciences, Inc. SG&A Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$205.5M
FY2025
5-year range
$26.2M / $205.5M
FY2021-FY2025
Trend
+138.3%
vs FY2024
Sector context
#68 of 213
Health Care
What the data says
At $206M, Avidity Biosciences, Inc.'s sg&a expense ranks #146 of 213 in the Health Care sector. SG&A Expense has increased for 7 consecutive years, from $2M in FY2018 to $206M in FY2025.
Based on SEC 10-K filings.
$206M in FY2025 with a 5-year CAGR of +72.5%.
Increased from $54M to $206M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +76.0%
- 5-Year CAGR
- +72.5%
- 10-Year CAGR
- -
Sector benchmark
#146 of 213 in Health CareTop 68% of 213This company $205.5M Sector average $722.3M
▼
-71.5% below sector average
Key checks
Key Insights
- Avidity Biosciences, Inc.'s sg&a expense has grown for 7 consecutive years.
- 5-year CAGR of +72.5%, indicating consistent growth.
- In FY2025, sg&a expense increased 138.3% year-over-year.
- Ranks #68 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $205.5M | +138.3% |
| FY2024 | $86.2M | +59.1% |
| FY2023 | $54.2M | +43.6% |
| FY2022 | $37.7M | +44.0% |
| FY2021 | $26.2M | +94.6% |
| FY2020 | $13.5M | +163.3% |
| FY2019 | $5.1M | +109.4% |
| FY2018 | $2.4M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026